Anticancer Immunity with Physical Treatment Modalities
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (1 June 2024) | Viewed by 2675
Special Issue Editor
Interests: redox medicine; immunology; cancer; cold physical plasma; reactive oxygen and nitrogen species; redox signaling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Physical treatment modalities are integral to adjuvant and neoadjuvant treatment schemes in oncology. In this context, numerous technologies are being experimentally and clinically investigated, such as radiotherapy, photodynamic therapy, cryotherapy, proton therapy, hyperthermia, pulsed electric field (PEF)-mediated electroporation (within electrochemotherapy), and gas plasma technology (also referred to as cold physical plasma, cold atmospheric pressure plasma, or nonthermal plasma). In recent years, many of these approaches have been suggested to support the cancer immunity cycle by inducing immunogenic cancer cell death (ICD) in conjunction with DAMPs (damage-associated molecular patterns). In combination with cancer immunotherapies, this may harness the power of antitumor immunity for promoting anticancer treatment responses. Submissions to this SI should focus on ICD-inducing physical modalities, potentially in the context of combination therapies, and molecular and immunological mechanisms thereof.
Dr. Sander Bekeschus
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunity cycle
- cryotherapy
- gas plasma technology
- hyperthermia
- immunogenic cell death (ICD)
- photodynamic therapy
- proton therapy
- pulsed electric fields
- radiotherapy
- ROS
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
